CLS Holdings USA Inc (CLSH)
0.054
0.00 (0.00%)
USD |
OTCM |
May 17, 15:59
CLS Holdings USA Enterprise Value: 12.64M for May 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 16, 2024 | 12.64M |
| May 15, 2024 | 12.64M |
| May 14, 2024 | 12.77M |
| May 13, 2024 | 12.46M |
| May 10, 2024 | 12.93M |
| May 09, 2024 | 12.77M |
| May 08, 2024 | 12.77M |
| May 07, 2024 | 12.45M |
| May 06, 2024 | 12.09M |
| May 03, 2024 | 12.09M |
| May 02, 2024 | 12.77M |
| May 01, 2024 | 12.77M |
| April 30, 2024 | 12.77M |
| April 29, 2024 | 12.43M |
| April 26, 2024 | 12.64M |
| April 25, 2024 | 12.77M |
| April 24, 2024 | 12.77M |
| April 23, 2024 | 12.77M |
| April 22, 2024 | 12.77M |
| April 19, 2024 | 12.77M |
| April 18, 2024 | 12.77M |
| April 17, 2024 | 12.77M |
| April 16, 2024 | 12.77M |
| April 15, 2024 | 12.77M |
| April 12, 2024 | 12.07M |
| Date | Value |
|---|---|
| April 11, 2024 | 12.14M |
| April 10, 2024 | 12.35M |
| April 09, 2024 | 12.60M |
| April 08, 2024 | 13.17M |
| April 05, 2024 | 12.15M |
| April 04, 2024 | 12.64M |
| April 03, 2024 | 12.64M |
| April 02, 2024 | 12.64M |
| April 01, 2024 | 12.04M |
| March 28, 2024 | 12.04M |
| March 27, 2024 | 12.04M |
| March 26, 2024 | 12.04M |
| March 25, 2024 | 12.04M |
| March 22, 2024 | 12.09M |
| March 21, 2024 | 12.09M |
| March 20, 2024 | 11.47M |
| March 19, 2024 | 12.09M |
| March 18, 2024 | 11.73M |
| March 15, 2024 | 11.40M |
| March 14, 2024 | 12.09M |
| March 13, 2024 | 12.09M |
| March 12, 2024 | 12.77M |
| March 11, 2024 | 12.09M |
| March 08, 2024 | 11.80M |
| March 07, 2024 | 11.81M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
11.35M
Minimum
Nov 15 2023
60.15M
Maximum
Feb 10 2021
27.87M
Average
29.04M
Median
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 5.209M |
| Palatin Technologies Inc | 23.43M |
| iBio Inc | 16.17M |
| Theriva Biologics Inc | -8.844M |
| Oragenics Inc | 5.770M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.369M |
| Revenue (Quarterly) | 4.926M |
| Total Expenses (Quarterly) | 5.365M |
| EPS Diluted (Quarterly) | -0.04 |
| Gross Profit Margin (Quarterly) | 43.17% |
| Profit Margin (Quarterly) | -88.69% |
| Earnings Yield | -203.7% |
| Normalized Earnings Yield | -126.86 |